VivoSeq
Gastroenterology

Crohn Disease (CD)

1

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Crohn Disease (CD) is an early-stage landscape with 1 program across 1 company. The most active players are Johnson & Johnson. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1

Guselkumab

Johnson & Johnson

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

Biomarker Discovery, Validation, and Multi-Omics Profiling for Disease Activity Assessment, Treatment Monitoring, and Risk Stratification in Inflammatory Bowel Disease: A Multicenter Prospective Biospecimen-Based Observational Cohort Study
Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·N/A·NCT07686406·6,000 enrolled
Optimal Care With Guselkumab In Crohn's Disease
Recruiting·GGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives·Approved·NCT07616687·210 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)